Synlogic Inc (NASDAQ:SYBX) insider Paul Francis Miller sold 3,000 shares of the firm’s stock in a transaction on Wednesday, June 20th. The shares were sold at an average price of $9.77, for a total transaction of $29,310.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Synlogic traded up $0.30, reaching $9.83, during mid-day trading on Friday, Marketbeat reports. The company had a trading volume of 157,184 shares, compared to its average volume of 135,863. Synlogic Inc has a 52 week low of $8.73 and a 52 week high of $23.00. The company has a market cap of $239.99 million, a PE ratio of -1.67 and a beta of 1.83.
Synlogic (NASDAQ:SYBX) last issued its quarterly earnings results on Tuesday, May 15th. The biotechnology company reported ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.18. The company had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.21 million. analysts forecast that Synlogic Inc will post -2.25 earnings per share for the current year.
A number of institutional investors have recently modified their holdings of SYBX. Spark Investment Management LLC bought a new stake in Synlogic in the 4th quarter valued at $105,000. Renaissance Technologies LLC bought a new stake in Synlogic in the 4th quarter valued at $191,000. Deutsche Bank AG boosted its holdings in Synlogic by 204.0% in the 4th quarter. Deutsche Bank AG now owns 19,672 shares of the biotechnology company’s stock valued at $190,000 after purchasing an additional 13,200 shares during the period. Texas Treasury Safekeeping Trust Co. bought a new stake in Synlogic in the 1st quarter valued at $975,000. Finally, Stanley Laman Group Ltd. bought a new stake in Synlogic in the 1st quarter valued at $249,000. 63.54% of the stock is owned by hedge funds and other institutional investors.
Synlogic Company Profile
Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.